A Cohort Study of Conversion From Aranesp® to NESP® for the Treatment of Anemia in Dialysis Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-11-30

Study Completion Date

2017-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective single-arm open-labeled cohort study on dialysis patients of the conversion from Aranesp® to NESP® for the treatment of anemia. The primary outcome of the study is the haemoglobin level after conversion to NESP® after 6 months. Secondary outcomes include the variability in haemoglobin level, average weekly dose of erythropoietin, safety profile of NESP®, patients' subjective assessment of fatigue and injection pain after the conversion.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of the Efficacy of Darbepoetin Alfa in the Treatment of Renal Anemia

NCT00563446

Anemia Kidney Failure, Chronic Peritoneal Dialysis, Continuous Ambulatory

COMPLETED NA

Darbepoetin Alfa Treatment of Anemia in Hemodialysis Subjects

NCT00119587

Anemia

COMPLETED PHASE3

An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD)

NCT00124098

Kidney Disease

COMPLETED PHASE3

Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease

NCT00925587

Anemia Chronic Kidney Disease

COMPLETED PHASE3

Renal Prognosis in Chronic Kidney Disease Patients With Hyporesponsive Anemia to Erythropoiesis Stimulating Agents

NCT02136563

Renal Anemia Chronic Kidney Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Currently in Hong Kong, Aranesp®, manufactured by Amgen® is the only available Darbepoetin alpha licensed. NESP®, a Darbepoetin alpha agent manufactured by Kirin®, will be replacing Aranesp®.It is important to evaluate the therapeutic equivalence of the two agents, and its efficacy, tolerability and safety profile in the treatment of anemia in dialysis patients. Moreover, a new maximum preparation of NESP 120® microgram will be available to replace the Aranesp® 100 microgram prefilled syringe at the same cost. This larger Darbepoetin alpha preparation may allow extension of dosing intervals. This may subsequently allow cost saving and better convenience to medical staff and patients.

The objectives of this project are:

1. To investigate the effectiveness of NESP® in the achieving a stable anemia control in chronic dialysis patients with the same dose conversion from Aranesp®
2. To investigate the effectiveness of increasing the dosing interval of NESP® (but maintaining the same total dose) in sustaining a stable anemia control in chronic dialysis patients
3. To explore the possibility of cost saving in administering a larger dose NESP® but at an extended interval

Patients will be divided into 3 groups.

Group A. Same dose conversion group

• Patients on stable low dose Aranesp® (on 20mcg preparations or on 40mcg every 2 weeks or less) will be converted to the same dose of NESP®

Group B. Attempt extension of dosing interval with higher dose of NESP® preparations

• Patients on stable dose of Aranesp® will be converted to higher dose preparation of NESP® (40 or 120 mcg preparations) with extended dosing intervals.

Group C. Attempt dosage saving with 120 mcg preparation

• Patients on Aranesp® 100mcg will be switched to the NESP® 120mcg preparation with slight increase in dosing interval

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anemia End Stage Renal Failure on Dialysis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Darbepoetin alfa (NESP®) same dose

Patients on stable low dose Aranesp® (darbepoetin alfa manufactured by Amgen®) (on 20mcg preparations or on 40mcg every 2 weeks or less) will be converted to the same dose of NESP® (darbepoetin alfa manufactured by Kirin®)

Group Type EXPERIMENTAL

Darbepoetin alfa

Intervention Type OTHER

Conversion from Aranesp® to NESP®

Extended dosing Darbepoetin alfa (NESP®)

Patients on stable dose of Aranesp® (darbepoetin alfa manufactured by Amgen®) will be converted to higher dose preparation of NESP® (darbepoetin alfa manufactured by Kirin®) 40 or 120 mcg preparations) with extended dosing intervals. The total dose of Darbepoetin alpha remains the same.

Group Type EXPERIMENTAL

Darbepoetin alfa

Intervention Type OTHER

Conversion from Aranesp® to NESP®

Darbepoetin alfa (NESP®) 120mcg

Patients on Aranesp® 100 mcg preparation (darbepoetin alfa manufactured by Amgen®) will be switched to the NESP® (darbepoetin alfa manufactured by Kirin®)120mcg preparation with slight increase in dosing interval according to the conversion

Group Type EXPERIMENTAL

Darbepoetin alfa

Intervention Type OTHER

Conversion from Aranesp® to NESP®

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Darbepoetin alfa

Conversion from Aranesp® to NESP®

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NESP

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult Chinese patients (age greater than or equal to 18)
* on long-term dialysis for at least 3 months
* on Aranesp® treatment for at least 3 months
* stable hemoglobin level within the range of 9 to12 g/dL, on the same stable dose of Aranesp® within the past 2 months.
* Minimum weekly kT/V of 1.7 for peritoneal dialysis patients and 1.2 per haemodialysis session for haemodialysis patients
* Able to give informed consent

Exclusion Criteria

Presence of

* thalassaemia
* haematological diseases
* severe hyperparathyroidism (PTH \>90 pmol/L)
* iron, vitamin B12 or folate deficiency
* uncontrolled malignancy
* active blood loss or hemolysis

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No